RA Session II, Taysha Gene Therapies CEO

Pre­lude to buy­out? Astel­las picks up Taysha stock, two gene ther­a­py pro­grams for $50M

Half a year af­ter Taysha Gene Ther­a­pies laid off 35% of its staffers and paused the bulk of its R&D work, the Dal­las crew has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA